Consequently, inhibition of PARP-mediated DNA repair was discovered to be an efficient approach to selectively kill tumor cells, which resulted in the development of small molecule PARP inhibitors (PARPi) that bind to the NAD+ binding pocket of the catalytic domain of PARP1 and prevent poly(ADP)-ribosylation [6,7,8,9,10]. This evidence concerns the gene PARP1 and neoplasm.